BioInvent: Updated ph2a data on BI-1808 in CTCL shared at EHA
At EHA, BioInvent shared updated phase 2a data on BI-1808 in CTCL. Among 9 evaluable CTCL patients (7 SS, 2 MF), results showed 1 CR (SS), 3 PRs (2 SS, 1 MF), and 5 SDs - resulting in an ORR of c. 45% and a DCR of 100%. In PTCL, 2 patients were evaluable with 1 PR and 1 SD. On the safety front, all
Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.